Eric Milledge New Chairman of DarioHealth Newly Established Scientific Advisory Board: Offers 40+ Years of Experience

Monday, September 21, 2020

September 16, 2020

Eric Milledge has joined DarioHealth as Chairman of the company’s newly-established Scientific Advisory Board (SAB).

Eric Milledge has worked in the healthcare field for his entire career, with a focus on pharmaceuticals and medical devices. With more than 34 years at Johnson & Johnson (JNJ) in roles of increasing responsibility, he built a vast network of relationships across the healthcare landscape.

As president of Ortho McNeil Pharmaceutical, Eric Milledge led in the licensing and successful introduction of levofloxacin (antibiotic), tramadol (analgesic), and the commercialization of topamax (anticonvulsant), building a multi-billion dollar U.S. pharmaceutical business. Eric also served as Company Group Chairman for Johnson & Johnson Healthcare Systems which oversaw the negotiation and management of JNJ’s medical device, diagnostic and pharmaceutical U.S. hospital contracts. Eric also served as Company Group Chairman of LifeScan Inc., the blood glucose division of JNJ. Under Eric’s leadership, LifeScan Global Diabetes franchise experienced rapid organic and inorganic growth, including the acquisition of Inverness Medical Technology’s Diabetes Care Products business. His leadership helped transform LifeScan into a global organization with thousands of employees and billions in annual revenues.

After retiring from JNJ, Eric served as chairman for a number of medical device startup companies including chairman of Nfocus Neuromedical, Symetis SA, and CeQur SA. Eric also served as an operating partner for Geneva-based Endeavour Vision Growth, a medical device growth fund. In this newly-formed role at DarioHealth Corp., Eric will be responsible for building out an SAB with renowned physicians who both understand and champion the benefits of digital therapeutics in managing complex chronic conditions.

Eric and the future SAB members will work alongside Dario’s research and development team and external partners to develop and implement the Company’s strategic roadmap for Dario’s technology platform. This includes expanding the company’s offering to address additional chronic conditions and integrating additional technologies such as a continuous glucose monitor (CGM). Activities will also include the generation of additional data supporting the use of Dario’s platform for managing chronic disease and acting as a reference resource for clients and potential clients in the business-to-business-to-consumer (B2B2C) channel. The primary objectives of this strategic initiative will be to help drive market awareness and the adoption of Dario’s digital health solution.

“I am excited to join Dario as the company continues to refine and improve its digital therapeutics platform,” stated Mr. Milledge. “I’m impressed with Dario’s ability to engage patients and drive clinically meaningful improvements through better management of their chronic conditions. With additional resources and the execution of the company’s strategic roadmap, I believe Dario will have a best-in-class platform that is unrivaled in the industry.”

“We are very pleased that Eric is spearheading our effort to assemble a world-class SAB,” commented Erez Raphael, Dario’s CEO. “He brings significant experience and knowledge relevant to our industry, and a vast network of thought leaders across the diabetes treatment landscape. We believe Eric can help take our technology to the next level by attracting scientific and strategic business partners who will strengthen our platform and ultimately our reputation as a pioneer and leader in digital therapeutics. We believe that our leadership position will improve our ability to execute within the B2B2C channel, winning new accounts and further penetrating the significant opportunity that already exists within our current customer base.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here